| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
PRF-110 promoted normal wound healing and prevented scar formation following surgical procedures
Company reaffirms it is on track to report top-line results from the Phase 3 trial in the second half of 2024
TEL AVIV, Israel, Aug. 05, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces positive wound healing data from its human clinical trials investigating the efficacy of PRF-110, the Company's lead asset designed to provide extended, non-opiate, post-surgical pain relief.
Building on extensive preclinical research, PainReform previously conducted wound healing studies in animal models which demonstrated that PRF-110 allows for normal wound healing of surgical incisions comparable to both Naropin® (ropivacaine) and saline. Importantly, these studies showed no adverse histological or radiologic effects on soft or bony tissues.
Posted In: PRFX
